Compare Eli Lilly And Co (LLY) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Manulife Financial Corporation — how do they compare? Eli Lilly And Co trades at $1,179.6 (market cap $1.02T), while Manulife Financial Corporation trades at $42.51 (market cap $69.96B). The key difference: Eli Lilly And Co is far larger — about 14.6× Manulife Financial Corporation's market cap, and Manulife Financial Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| LLY | MFC | |
|---|---|---|
Market Cap | $1.02T | $69.96B |
Sector | Health | Financials |
52-Week High | $1.24K | $43.39 |
52-Week Low | $625.65 | $29.90 |
Enterprise Value | $1.06T | $66.52B |
Dividend Yield | 0.6% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,175.15, down 0.33% on the day, with a bullish technical signal and strong fundamental momentum. Revenue surged to $65.18B in 2025, with net income reaching $20.64B, and the company has beaten earnings estimates for three consecutive quarters. Recent news includes a lawsuit from Novo Nordisk over weight-loss drug advertising, but analyst sentiment remains overwhelmingly positive with a $1,380 consensus price target.
Outlook is supported by robust earnings growth and high profitability margins, but risks include competitive pressures and elevated valuation multiples. The stock's current price is near key resistance at $1,174, with institutional buying activity indicating continued confidence in Lilly's growth trajectory in the pharmaceutical sector.
MFC trades at $42.83, down 1.29% today, with a bullish technical signal supported by moving averages. The company reported revenue of $53.01B in 2025 and net income of $5.78B, with a P/E of 17.39. Recent news highlights AI advancements and strong Asia performance, while Q1 2026 earnings missed expectations. Analyst consensus is 57% buy with no sell ratings.
Outlook remains positive driven by AI initiatives and Asia growth, but risks include Q1 earnings miss and regulatory scrutiny. The stock offers steady profitability and dividend income, yet faces headwinds from wealth management outflows and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
